Price Change to Note: Could Diplomat Pharmacy Inc Crash Even More? The Stock Just Made Yearly Low

Price Change to Note: Could Diplomat Pharmacy Inc Crash Even More? The Stock Just Made Yearly Low

The stock of Diplomat Pharmacy Inc (NYSE:DPLO) hit a new 52-week low and has $21.34 target or 5.00% below today’s $22.46 share price. The 6 months bearish chart indicates high risk for the $1.45B company. The 1-year low was reported on Nov, 2 by Barchart.com. If the $21.34 price target is reached, the company will be worth $72.50M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 1.42 million shares traded hands or 60.53% up from the average. Diplomat Pharmacy Inc (NYSE:DPLO) has declined 17.59% since March 31, 2016 and is downtrending. It has underperformed by 20.11% the S&P500.

Diplomat Pharmacy Inc (NYSE:DPLO) Ratings Coverage

Out of 8 analysts covering Diplomat Pharmacy (NYSE:DPLO), 4 rate it a “Buy”, 0 “Sell”, while 4 “Hold”. This means 50% are positive. Diplomat Pharmacy has been the topic of 11 analyst reports since August 4, 2015 according to StockzIntelligence Inc. Mizuho maintained Diplomat Pharmacy Inc (NYSE:DPLO) rating on Wednesday, October 21. Mizuho has “Buy” rating and $44 price target. The firm earned “Neutral” rating on Wednesday, October 14 by Bank of America. The stock has “Market Perform” rating given by Cowen & Co on Friday, June 24. The firm has “Neutral” rating by Mizuho given on Wednesday, May 11. The stock of Diplomat Pharmacy Inc (NYSE:DPLO) earned “Neutral” rating by Bank of America on Tuesday, June 7. UBS initiated it with “Buy” rating and $35 target price in Wednesday, October 21 report. The firm earned “Outperform” rating on Tuesday, August 4 by Leerink Swann. The stock has “Overweight” rating given by Barclays Capital on Wednesday, January 6. Morgan Stanley downgraded Diplomat Pharmacy Inc (NYSE:DPLO) rating on Friday, October 2. Morgan Stanley has “Equal-Weight” rating and $31 price target.

According to Zacks Investment Research, “Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. It aids in the dispensing, delivery, dosing and reimbursement of clinically intensive and specialty drugs. The company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, HIV, specialized infusion therapy and many other serious or long-term conditions. Diplomat Pharmacy, Inc. is headquartered in Flint, Michigan.”

Insitutional Activity: The institutional sentiment decreased to 1.43 in 2016 Q2. Its down 0.22, from 1.65 in 2016Q1. The ratio is negative, as 17 funds sold all Diplomat Pharmacy Inc shares owned while 46 reduced positions. 23 funds bought stakes while 67 increased positions. They now own 50.07 million shares or 2.77% more from 48.72 million shares in 2016Q1.
Moreover, New York State Teachers Retirement Systems has 0% invested in Diplomat Pharmacy Inc (NYSE:DPLO) for 34,202 shares. Janus Capital Limited Liability Company accumulated 0.18% or 6.20 million shares. Comerica Bank & Trust has invested 0.01% of its portfolio in Diplomat Pharmacy Inc (NYSE:DPLO). Pub Sector Pension Inv Board accumulated 25,400 shares or 0.01% of the stock. The United Kingdom-based Legal General Group Public Ltd Com has invested 0% in Diplomat Pharmacy Inc (NYSE:DPLO). Fmr Ltd Co accumulated 1.12 million shares or 0.01% of the stock. Bank Of America De has 107,707 shares for 0% of their US portfolio. Denver Inv Advsr Lc last reported 0.14% of its portfolio in the stock. Prudential Finance Incorporated last reported 88,620 shares in the company. Manufacturers Life Insurance Communications The last reported 0% of its portfolio in the stock. Federated Invsts Pa reported 456,300 shares or 0.05% of all its holdings. National Bank & Trust owns 13,270 shares or 0.01% of their US portfolio. State Of Tennessee Treasury Department last reported 28,220 shares in the company. Riverbridge Prtn Ltd Limited Liability Company accumulated 0.51% or 704,785 shares. Raymond James & Associates accumulated 0% or 31,352 shares.

Insider Transactions: Since August 1, 2016, the stock had 0 insider buys, and 2 sales for $1.04 million net activity. Kaddis Atheer A had sold 20,000 shares worth $602,358.

More news for Diplomat Pharmacy Inc (NYSE:DPLO) were recently published by: Fool.com, which released: “Why Diplomat Pharmacy, Inc. Shares Are Falling 13.6% Today” on October 26, 2016. Blogs.Wsj.com‘s article titled: “CFO Moves: Newmont Mining, Varian Medical Systems, Diplomat Pharmacy, Nokia” and published on October 27, 2016 is yet another important article.

DPLO Company Profile

Diplomat Pharmacy, Inc. (Diplomat), incorporated on March 26, 1975, operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialized infusion therapy, and various other serious and/or long-term conditions. The Firm operates through specialty pharmacy services segment. The Firm provides specialty pharmacy support services to a national network of retailers and independent pharmacy groups, hospitals and health systems. The Firm offers various services, such as specialty drug dispensing, retail specialty services, hospital and health system services, and hub services. The Company’s specialty drug dispensing services include patient care coordination, clinical services, compliance and persistency programs, patient financial assistance, specialty pharmacy training/consulting (Diplomat University), benefits investigation, prior authorization and risk evaluation and medication strategy (REMS).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Tags: , ,

Related posts

Leave a Comment